Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy.

OBJECTIVE The purpose of this study was to examine whether longitudinally sampled maternal angiogenic concentrations predict preeclampsia. STUDY DESIGN Plasma sFlt-1 and placental growth factor (PlGF) concentrations in healthy pregnant women were quantified at 10, 17, 25, and 35 weeks' gestation. Preeclampsia was diagnosed with criteria from the American College of Obstetricians and Gynecologists. RESULTS In the first trimester, sensitivity/specificity for PlGF and sFlt-1 were 55/43% and 57/40%, respectively, and did not improve appreciably as the pregnancy progressed. Among pregnancies that later experienced preeclampsia, median PlGF was lower beginning in the second trimester, but sFlt-1 was not higher until the third trimester. Analyte positive predictive values approached 10% in the third trimester. Negative predictive values were >90% for the entire pregnancy. CONCLUSION Prediction of preeclampsia in early pregnancy was not possible with the use of maternal angiogenic protein concentrations. Even in late pregnancy, positive predictive values were not useful clinically. Negative predictive values are similarly unlikely to prove useful as a tool with which to a rule out suspected disease.

[1]  James M. Roberts,et al.  Contemporary concepts of the pathogenesis and management of preeclampsia. , 2002, JAMA.

[2]  F. Corrado,et al.  Endoglin, PlGF and sFlt‐1 as markers for predicting pre‐eclampsia , 2008, Acta obstetricia et gynecologica Scandinavica.

[3]  W. B. Robertson,et al.  The physiological response of the vessels of the placental bed to normal pregnancy. , 1967, The Journal of pathology and bacteriology.

[4]  D. Saller,et al.  Second‐Trimester Maternal Serum Placental Growth Factor and Vascular Endothelial Growth Factor for Predicting Severe, Early‐Onset Preeclampsia , 2003, Obstetrics and gynecology.

[5]  Robert N. Taylor,et al.  Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. , 2003, American journal of obstetrics and gynecology.

[6]  R. Hoover,et al.  Blood pressure augmentation and maternal circulating concentrations of angiogenic factors at delivery in preeclamptic and uncomplicated pregnancies. , 2008, American journal of obstetrics and gynecology.

[7]  Jm Roberts,et al.  Pathogenesis and genetics of pre-eclampsia , 2001, The Lancet.

[8]  Robert N. Taylor,et al.  First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. , 2004, The Journal of clinical endocrinology and metabolism.

[9]  J. Elema,et al.  MORPHOLOGICAL CHANGES OF THE SPIRAL ARTERIES IN THE PLACENTAE BED IN RELATION TO PRE‐ECLAMPSIA AND FETAL GROWTH RETARDATION , 1981, British journal of obstetrics and gynaecology.

[10]  J. Haigh,et al.  Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. , 2003, The Journal of clinical investigation.

[11]  J. Dudenhausen,et al.  An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. , 2010, American journal of obstetrics and gynecology.

[12]  N. Berkane,et al.  Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. , 2004, Clinical chemistry.

[13]  B. Sibai,et al.  Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. , 2010, American journal of obstetrics and gynecology.

[14]  R. Romero,et al.  Inflammation in pregnancy: its roles in reproductive physiology, obstetrical complications, and fetal injury. , 2007, Nutrition reviews.

[15]  C. Damsky,et al.  Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? , 1997, The Journal of clinical investigation.

[16]  K. Nicolaides,et al.  First‐Trimester Maternal Serum Levels of Placenta Growth Factor as Predictor of Preeclampsia and Fetal Growth Restriction , 2001, Obstetrics and gynecology.

[17]  R. Romero,et al.  Circulating angiogenic and antiangiogenic factors in women with eclampsia. , 2011, American journal of obstetrics and gynecology.

[18]  A. W. Woods,et al.  Rheological and Physiological Consequences of Conversion of the Maternal Spiral Arteries for Uteroplacental Blood Flow during Human Pregnancy , 2009, Placenta.

[19]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia , 2003 .

[20]  W. B. Robertson,et al.  The role of the spiral arteries in the pathogenesis of preeclampsia. , 1972, Obstetrics and gynecology annual.

[21]  B. Sibai,et al.  Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. , 2006, The New England journal of medicine.

[22]  R. Romero,et al.  An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. , 2005, American journal of obstetrics and gynecology.

[23]  James M. Roberts,et al.  Pregnancy-Related Hypertension , 2009 .

[24]  S. Karumanchi,et al.  Angiogenic dysfunction in molar pregnancy. , 2007, American journal of obstetrics and gynecology.

[25]  L. Vatten,et al.  Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. , 2007, American journal of obstetrics and gynecology.

[26]  K. Lim,et al.  Circulating angiogenic factors and the risk of preeclampsia. , 2004, The New England journal of medicine.

[27]  I. Sargent,et al.  Latest Advances in Understanding Preeclampsia , 2005, Science.

[28]  R. Ness,et al.  Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. , 2005, The Journal of clinical endocrinology and metabolism.

[29]  N. Bersinger,et al.  First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. , 2008, American journal of obstetrics and gynecology.

[30]  K. Nicolaides,et al.  Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre‐eclampsia , 2008, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[31]  K. Lim,et al.  Circulating Factors as Markers and Mediators of Endothelial Cell Dysfunction in Preeclampsia , 1998, Seminars in reproductive endocrinology.

[32]  R. Romero,et al.  Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia , 2005, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[33]  M. Maresh,et al.  Maternal Fetal Medicine. Principles and Practice , 1989 .

[34]  Wenjiang J. Fu,et al.  The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age , 2008, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[35]  N. Veall,et al.  THE MATERNAL PLACENTAL BLOOD FLOW IN NORMOTENSIVE AND HYPERTENSIVE WOMEN , 1953, The Journal of obstetrics and gynaecology of the British Empire.

[36]  R. Resnik,et al.  Creasy and Resnik's Maternal-Fetal Medicine: Principles and Practice , 2013 .